Tipping the balance: A biased nanobody antagonist of CCR3 with potential for the treatment of eosinophilic inflammation

To a large extent, eosinophil recruitment in both homeostasis and allergy is dependent on the eotaxin family of chemokines. CCL11/eotaxin-1 was the first chemokine discovered to have high selectivity for eosinophils through use of a guinea pig model of allergic airway disease.1 After cloning of mouse and human eotaxin orthologues, CCR3 was identified as the eotaxin-1 receptor, which is expressed at high levels on the surfaces of eosinophils.2 Two other eotaxins, CCL24/eotaxin-2 and CCL26/eotaxin-3, were discovered, both showing high selectivity for CCR3. (Source: Journal of Allergy and Clinical Immunology)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2LbQYNu